Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.38 |
| ▸ | NEK2 | P51955 | 1/20 | 0.37 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13008472 | 0.91 | ALDH1A1 (0.46) | ALDH1A1GAAL3MBTL1POLBPTGES2 | |
| SCHEMBL1594145 | 0.90 | ALDH1A1 (0.48) | ALDH1A1GAAL3MBTL1POLBPTGES2 | |
| SCHEMBL1594835 | 0.88 | ALDH1A1 (0.46) | ALDH1A1GAAL3MBTL1POLBSIGMAR1 | |
| SCHEMBL15905581 | 0.87 | ALDH1A1 (0.46) | ALDH1A1GAAL3MBTL1POLBPTGES2 | |
| SCHEMBL1594036 | 0.87 | ALDH1A1 (0.46) | ALDH1A1GAAL3MBTL1POLBSIGMAR1 | |
| SCHEMBL1594222 | 0.86 | ALDH1A1 (0.47) | ALDH1A1GAAL3MBTL1POLBPTGES2 | |
| SCHEMBL14953395 | 0.85 | ALDH1A1 (0.47) | ALDH1A1GAAL3MBTL1POLBSIGMAR1 | |
| SCHEMBL12620551 | 0.80 | ALDH1A1 (0.55) | ALDH1A1GAAL3MBTL1POLBPTGES2 | |
| SCHEMBL4244410 | 0.78 | ALDH1A1 (0.53) | ALDH1A1GAAL3MBTL1POLBPTGES2 | |
| SCHEMBL4246156 | 0.76 | ALDH1A1 (0.51) | ALDH1A1GAAL3MBTL1POLBPTGES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791137-B2 | Therapeutic compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2014-07-29 | — | — | US | disclosed |
| US-8791137-B2 | Therapeutic compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2014-07-29 | — | — | US | disclosed |
| US-8399487-B2 | Pyrazole compounds and uses thereof | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-03-19 | — | — | US | disclosed |
| US-8399487-B2 | Pyrazole compounds and uses thereof | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-03-19 | — | — | US | disclosed |
| EP-2465850-A1 | THERAPEUTIC COMPOUNDS | Helicon Therapeutics, Inc. (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20110160248-A1 | PYRAZOLE COMPOUNDS AND USES THEREOF | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-06-30 | — | — | US | disclosed |
| US-20110160248-A1 | PYRAZOLE COMPOUNDS AND USES THEREOF | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-06-30 | — | — | US | disclosed |
| US-7919626-B2 | Pyrazole compounds and uses thereof | HELICON THERAPEUTICS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919626-B2 | Pyrazole compounds and uses thereof | HELICON THERAPEUTICS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20100317648-A1 | THERAPEUTIC COMPOUNDS | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2010-12-16 | — | — | US | disclosed |
| US-20100317648-A1 | THERAPEUTIC COMPOUNDS | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2010-12-16 | — | — | US | disclosed |
| WO-2007100851-A1 | THERAPEUTIC COMPOUNDS | HELICON THERAPEUTICS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| US-20070203154-A1 | Therapeutic Compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2007-08-30 | — | — | US | disclosed |
| US-20070203154-A1 | Therapeutic Compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317648-A1 | THERAPEUTIC COMPOUNDS | MAOB, MAOA, HTR1B | ALDH1A1 455/4885GAA 76/4885L3MBTL1 1819/4885 |
| US-20110160248-A1 | PYRAZOLE COMPOUNDS AND USES THEREOF | MAOB, MAOA, HTR1B | ALDH1A1 602/4885GAA 400/4885L3MBTL1 2501/4885 |
| US-20070203154-A1 | Therapeutic Compounds | MAOB, MAOA, HTR1B | ALDH1A1 455/4885GAA 76/4885L3MBTL1 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.